CStone Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
CStone Pharmaceuticals has a total shareholder equity of CN¥467.7M and total debt of CN¥306.4M, which brings its debt-to-equity ratio to 65.5%. Its total assets and total liabilities are CN¥1.5B and CN¥1.1B respectively.
Key information
65.5%
Debt to equity ratio
CN¥306.42m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥857.65m |
| Equity | CN¥467.66m |
| Total liabilities | CN¥1.06b |
| Total assets | CN¥1.53b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PH4's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥713.2M).
Long Term Liabilities: PH4's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥351.2M).
Debt to Equity History and Analysis
Debt Level: PH4 has more cash than its total debt.
Reducing Debt: PH4's debt to equity ratio has increased from 0% to 65.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PH4 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PH4 has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 8.1% each year.